Identification and Validation of a Novel Three Hub Long Noncoding RNAs With m6A Modification Signature in Low-Grade Gliomas

It has been evident that N6-methyladenosine (m6A)-modified long noncoding RNAs (m6A-lncRNAs) involves regulating tumorigenesis, invasion, and metastasis for various cancer types. In this study, we sought to pick computationally up a set of 13 hub m6A-lncRNAs in light of three state-of-the-art tools WGCNA, iWGCNA, and oCEM, and interrogated their prognostic values in brain low-grade gliomas (LGG). Of the 13 hub m6A-lncRNAs, we further detected three hub m6A-lncRNAs as independent prognostic risk factors, including HOXB-AS1, ELOA-AS1, and FLG-AS1. Then, the m6ALncSig model was built based on these three hub m6A-lncRNAs. Patients with LGG next were divided into two groups, high- and low-risk, based on the median m6ALncSig score. As predicted, the high-risk group was more significantly related to mortality. The prognostic signature of m6ALncSig was validated using internal and external cohorts. In summary, our work introduces a high-confidence prognostic prediction signature and paves the way for using m6A-lncRNAs in the signature as new targets for treatment of LGG.